JP2014221052A5 - - Google Patents

Download PDF

Info

Publication number
JP2014221052A5
JP2014221052A5 JP2014129350A JP2014129350A JP2014221052A5 JP 2014221052 A5 JP2014221052 A5 JP 2014221052A5 JP 2014129350 A JP2014129350 A JP 2014129350A JP 2014129350 A JP2014129350 A JP 2014129350A JP 2014221052 A5 JP2014221052 A5 JP 2014221052A5
Authority
JP
Japan
Prior art keywords
hpv45
yeast
nucleic acid
protein
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014129350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014221052A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014221052A publication Critical patent/JP2014221052A/ja
Publication of JP2014221052A5 publication Critical patent/JP2014221052A5/ja
Pending legal-status Critical Current

Links

JP2014129350A 2003-09-29 2014-06-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現 Pending JP2014221052A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
US60/506,812 2003-09-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011045589A Division JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016019712A Division JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Publications (2)

Publication Number Publication Date
JP2014221052A JP2014221052A (ja) 2014-11-27
JP2014221052A5 true JP2014221052A5 (enExample) 2015-08-06

Family

ID=34421558

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006528190A Expired - Lifetime JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2014129350A Pending JP2014221052A (ja) 2003-09-29 2014-06-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006528190A Expired - Lifetime JP5451960B2 (ja) 2003-09-29 2004-09-24 酵母におけるｈｐｖ４５ｌ１の最適化された発現
JP2011045589A Pending JP2011152137A (ja) 2003-09-29 2011-03-02 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016019712A Pending JP2016136947A (ja) 2003-09-29 2016-02-04 酵母におけるｈｐｖ４５ｌ１の最適化された発現

Country Status (33)

Country Link
US (2) US7250170B2 (enExample)
EP (1) EP1673106B1 (enExample)
JP (4) JP5451960B2 (enExample)
KR (1) KR101165278B1 (enExample)
CN (1) CN1859923B (enExample)
AR (2) AR045804A1 (enExample)
AT (1) ATE435029T1 (enExample)
AU (1) AU2004277934B2 (enExample)
BE (1) BE2015C072I2 (enExample)
BR (1) BRPI0414845B8 (enExample)
CA (1) CA2539168C (enExample)
CY (2) CY1110525T1 (enExample)
DE (1) DE602004021828D1 (enExample)
DK (1) DK1673106T3 (enExample)
ES (1) ES2327530T3 (enExample)
FR (1) FR15C0083I2 (enExample)
HU (1) HUS1500063I1 (enExample)
IL (1) IL174458A (enExample)
IS (1) IS2694B (enExample)
LT (2) LTC1673106I2 (enExample)
LU (1) LU92902I2 (enExample)
MX (1) MXPA06003457A (enExample)
MY (1) MY140664A (enExample)
NL (1) NL300776I1 (enExample)
NO (3) NO339932B1 (enExample)
NZ (1) NZ545834A (enExample)
PL (1) PL1673106T3 (enExample)
PT (1) PT1673106E (enExample)
RU (1) RU2360001C2 (enExample)
SI (1) SI1673106T1 (enExample)
TW (1) TWI350853B (enExample)
WO (1) WO2005032586A1 (enExample)
ZA (1) ZA200601961B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
RU2373219C2 (ru) * 2004-03-24 2009-11-20 Мерк энд Ко. Инк. Оптимизированная экспрессия hpv 52 l1 в дрожжах
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7691579B2 (en) 2005-04-15 2010-04-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1877086A2 (en) * 2005-04-26 2008-01-16 GlaxoSmithKline Biologicals SA Vaccine
WO2008026869A1 (en) * 2006-08-28 2008-03-06 Sungkyunkwan University Foundation For Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
US8795676B2 (en) * 2007-11-23 2014-08-05 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma virus
CN102215861B (zh) 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
AU2011258501B2 (en) 2010-05-25 2016-07-07 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
EP2722389B1 (en) 2011-06-15 2018-03-07 Hong Jin Kim Method for enhancing the production yield of human papillomavirus l1 protein
CA2834618C (en) 2011-06-24 2020-11-03 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
MA40624A (fr) * 2014-09-11 2016-03-17 Cadila Healthcare Ltd Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
AU2021219652A1 (en) 2020-02-14 2022-08-18 Merck Sharp & Dohme Llc HPV vaccine
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
TW202315602A (zh) 2021-08-19 2023-04-16 美商默沙東有限責任公司 新穎熱穩定脂質奈米粒子及其使用方法
AR132886A1 (es) 2023-06-09 2025-08-06 Merck Sharp & Dohme Llc Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693203B2 (en) * 1994-05-16 1998-06-25 Merck Sharp & Dohme Corp. Papillomavirus vaccines
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EP0969862B1 (en) 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetic hiv gag genes
EP1015612B1 (en) * 1997-05-27 2005-01-26 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
WO1999002694A1 (en) 1997-07-09 1999-01-21 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
CA2339324C (en) * 1998-08-14 2011-05-31 Robert S. Lowe Protein delivery system using human papillomavirus virus-like particles
SK2232001A3 (en) * 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
WO2000039151A1 (en) * 1998-12-23 2000-07-06 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CZ2003180A3 (cs) 2000-07-21 2003-08-13 Glaxo Group Limited Papilomavirové sekvence s optimalizovanými kodony
AU2003217413A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR101080628B1 (ko) 2003-03-24 2011-11-08 머크 샤프 앤드 돔 코포레이션 효모에서 ｈｐｖ 31 ｌ1의 최적 발현

Similar Documents

Publication Publication Date Title
JP2014221052A5 (enExample)
JP2011152137A5 (enExample)
JP2012095652A5 (enExample)
JP2013533745A5 (enExample)
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
CA2539168A1 (en) Optimized expression of hpv 45 l1 in yeast
JP2012140448A5 (enExample)
CA2543928A1 (en) Optimized expression of hpv 58 l1 in yeast
JP2011507532A5 (enExample)
CA2519112A1 (en) Optimized expression of hpv 31 l1 in yeast
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
JP2010533737A5 (enExample)
RU2019139064A (ru) Композиции и способы для лечения цитомегаловируса
RU2006137363A (ru) Оптимизированная экспрессия hpv 52 l1 в дрожжах
HK1203522A1 (en) Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
JP2013517773A5 (enExample)
RU2012122166A (ru) Способы получения рекомбинантных белков с увеличенными эффективностями секреции
JP2015521848A5 (enExample)
JP2016513457A5 (enExample)
WO2011034953A3 (en) Lassa virus-like particles and methods of production thereof
ZA202100384B (en) Influenza virus hemagglutinin mutants
CN103361327A (zh) 异源高效表达脂肪酶的重组毕赤酵母
JP2016507520A5 (enExample)
JP2023024998A5 (enExample)